Efficacy of mulberry leaf tablets in patients with mild dyslipidemia

Phytother Res. 2011 Mar;25(3):365-9. doi: 10.1002/ptr.3270.

Abstract

Mulberry leaf is well known for its several biological effects. The purpose of this study was to evaluate the hypolipidemic effect of mulberry leaf in non-diabetic patients with mild dyslipidemia. A within-subjects research design was conducted at the out-patient clinic in Thailand. Twenty-three patients who met the NCEP ATP III criteria guideline for dyslipidemia and failed a 4 week diet therapy were enrolled and assigned to receive three tablets of 280 mg mulberry leaf tablet three times a day before meals for a period of 12 weeks. Routine blood analyses including lipid parameters and liver function tests were performed every 4 weeks. At 4 and 8 weeks of mulberry leaf tablet therapy, triglyceride was significantly decreased by 10.2% (p < 0.05) and 12.5% (p < 0.05), respectively, from baseline. At the end of the study, total cholesterol, triglyceride and LDL were significantly decreased by 4.9% (p < 0.05), 14.1% (p < 0.05) and 5.6% (p < 0.05), respectively, from baseline, whereas HDL was significantly increased by 19.7% (p < 0.05). Even though some patients experienced side effects such as mild diarrhea (26%), dizziness (8.7%) or constipation and bloating (4.3%), mulberry leaf tablet therapy is still capable and safe in reducing cholesterol levels and enhancing HDL in patients with mild dyslipidemia.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Dyslipidemias / diet therapy
  • Dyslipidemias / drug therapy*
  • Energy Intake
  • Female
  • Humans
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / therapeutic use*
  • Male
  • Morus / chemistry*
  • Phytotherapy*
  • Plant Leaves / chemistry
  • Tablets / administration & dosage
  • Tablets / therapeutic use
  • Thailand

Substances

  • Hypolipidemic Agents
  • Tablets